—Conference Call to Take Place Tomorrow,
Tuesday, May 28, 2024, at 8:00 am
ET—
BRIDGEWATER, N.J., May 27, 2024
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global
biopharmaceutical company on a mission to transform the lives of
patients with serious and rare diseases, today announced that it
will host a conference call and webcast tomorrow, Tuesday, May 28, 2024, at 8:00 am ET to discuss topline results from the
ASPEN study, a global, randomized,
double-blind, placebo-controlled Phase 3 study to assess the
efficacy, safety, and tolerability of brensocatib in patients with
non-cystic fibrosis bronchiectasis. The Company plans to issue a
press release sharing the topline results at approximately
6:30 am ET tomorrow, prior to the
start of the conference call.
Conference Call
Shareholders and other interested parties may participate in the
conference call by dialing (800) 715-9871 (U.S.) or (646) 307-1963
(international) and referencing access code 1245105. The call will
also be webcast live on the Company's website at
www.insmed.com.
A replay of the conference call will be accessible approximately
one hour after its completion through June 27, 2024, by
dialing (800) 770-2030 (U.S.) or (609) 800-9909 (international) and
referencing access code 1245105. A webcast of the call will also be
archived for 90 days under the Investor Relations section of the
Company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is a first-in-disease
therapy approved in the United States, Europe,
and Japan to treat a chronic, debilitating lung disease.
The Company is progressing a robust pipeline of investigational
therapies targeting areas of serious unmet need, including
neutrophil-mediated inflammatory diseases and rare pulmonary
disorders. Insmed is also advancing an early-stage research engine
encompassing a wide range of technologies and modalities, including
artificial intelligence-driven protein engineering, gene therapy,
and protein manufacturing. Insmed is headquartered
in Bridgewater, New Jersey, with additional offices and
research locations throughout the United States, Europe,
and Japan. Visit www.insmed.com to learn more.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-investor-call-to-discuss-topline-results-from-phase-3-aspen-study-of-brensocatib-in-patients-with-bronchiectasis-302156113.html
SOURCE Insmed Incorporated
